2021 Jan 20;333102421989247 doi: 10.1177/0333102421989247. Online ahead of print.

Hans Christoph Diener Messoud AshinaIsabelle Durand-ZaleskiTobias KurthMichel Lantéri-MinetRichard B LiptonDaniel A OllendorfPatricia Pozo-RosichCristina TassorelliGisela Terwindt


The Clinical Trials Subcommittee of the International Headache Society presents the first Health Technology Assessment for the Acute Treatment of Migraine Attacks and Prevention of Migraine. Health technology assessments are systematic evaluations of the properties, effects, and consequences of healthcare technologies; this position statement is designed to inform decision makers about access to and reimbursement for medications and devices for the acute and preventive treatment of migraine. This position statement extends beyond the already available guidelines on randomized controlled trials for migraine to incorporate real-world evidence and a synthetic approach for considering multiple data sources and modelling methods when assessing the value of migraine treatments.

Keywords: Health technology assessment (HTA); International Headache Society (IHS); acute therapy; migraine; position statement; preventive treatment.

Health technology assessment for the acute and preventive treatment of migraine: A position statement of the International Headache Society